What is SmartLabs?
SmartLabs operates at the intersection of real estate and biotechnology, offering a specialized platform that minimizes the administrative and logistical burdens typically associated with scaling research operations. By providing in-house design, architecture, construction management, and full-service facilities management, SmartLabs enables organizations of varying sizes to focus on core scientific innovation rather than infrastructure maintenance. Headquartered in Boston, the company has established itself as a critical partner for firms seeking to accelerate their development timelines through high-quality, shared research amenities.
How much funding has SmartLabs raised?
SmartLabs has raised a total of $387.8M across 4 funding rounds:
Angel/Seed
$8.8M
Series A
$81M
Series B
$250M
Series C
$48M
Angel/Seed (2015): $8.8M, investors not publicly disclosed
Series A (2020): $81M, investors not publicly disclosed
Series B (2021): $250M supported by Winslow Capital Management, Onex Falcon, Conversion Venture Capital, Breed’s Hill Capital, and ArrowMark Partners
Series C (2024): $48M featuring Conversion Venture Capital, Winslow Capital Management, and ArrowMark Partners
Key Investors in SmartLabs
Conversion Venture Capital
CVC2 is a private equity and venture capital firm that invests its own capital alongside management teams and entrepreneurs to build segment-leading businesses.
Winslow Capital Management
Founded in 1992, Winslow Capital is a premier growth equity investment firm headquartered in Minneapolis, Minnesota.
ArrowMark Partners
Established in 2007, ArrowMark Partners is an employee-owned asset manager with specialized expertise in alternative credit and growth equity asset classes.
What's next for SmartLabs?
With the successful closure of this major strategic investment, SmartLabs is well-positioned to scale its footprint and enhance its service offerings. The capital will likely be deployed to expand its network of research environments, potentially entering new geographic markets to meet the rising demand for flexible, high-performance laboratory space. As the life sciences industry continues to prioritize agility and cost-efficiency, SmartLabs' model of providing integrated, pharma-grade infrastructure is expected to remain a key driver of its long-term market leadership and operational growth.
See full SmartLabs company page
